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Abstract Angiogenesis is essential for tumor growth and
metastatic potential and for that reason considered an
important target for tumor treatment. Noninvasive imaging
technologies, capable of visualizing tumor angiogenesis
and evaluating the efﬁcacy of angiostatic therapies, are
therefore becoming increasingly important. Among the
various imaging modalities, magnetic resonance imaging
(MRI) is characterized by a superb spatial resolution and
anatomical soft-tissue contrast. Revolutionary advances in
contrast agent chemistry have delivered versatile angio-
genesis-speciﬁc molecular MRI contrast agents. In this
paper, we review recent advances in the preclinical appli-
cation of paramagnetic and ﬂuorescent liposomes for
noninvasive visualization of the molecular processes
involved in tumor angiogenesis. This liposomal contrast
agent platform can be prepared with a high payload of
contrast generating material, thereby facilitating its detec-
tion, and is equipped with one or more types of targeting
ligands for binding to speciﬁc molecules expressed at the
angiogenic site. Multimodal liposomes endowed with
contrast material for complementary imaging technologies,
e.g., MRI and optical, can be exploited to gain important
preclinical insights into the mechanisms of binding and
accumulation at angiogenic vascular endothelium and to
corroborate the in vivo ﬁndings. Interestingly, liposomes
can be designed to contain angiostatic therapeutics,
allowing for image-supervised drug delivery and sub-
sequent monitoring of therapeutic efﬁcacy.
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Introduction
Inhibition of tumor angiogenesis is a modern and popular
approach to ﬁght tumor progression [1, 2]. Therapeutic
interventions aimed at reducing tumor growth by angio-
genesis inhibition are rapidly ﬁnding their way into clinical
practice [2]. The origin of this approach is that angiogen-
esis inhibitors target cells that support tumor growth, i.e.,
endothelial cells, instead of targeting the tumor cells
directly. Endothelial cells are genetically more stable than
tumor cells and thus less likely to develop drug resistance.
Moreover, the endothelial cells are directly accessible from
the bloodstream, enabling nanocarriers with a high payload
of angiostatic drugs to reach their target site efﬁciently.
There are several classes of angiostatic drugs, e.g., growth
factor blockers [3], growth factor signaling inhibitors,
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proliferation and migration inhibitors [5–7]. In 2004, the
Food and Drug Administration approved the ﬁrst angio-
static drug (Avastin) for human application [8].
These developments call for new noninvasive readouts
to test the efﬁcacy of novel angiostatic drugs. In a pre-
clinical setting, different methods are available to monitor
changes in angiogenic activity during the course of treat-
ment. Typically, new agents are ﬁrst evaluated in vitro
before further assessment in animal models. Inhibition or
regression of the volume of a subcutaneously implanted
tumor can be estimated by an external morphological
measurement, e.g., using a caliper. Such measurements are
often inaccurate, as they do not account for inward growth,
irregular tumor shape with multiple lobes and development
of metastases. Moreover, morphological changes often
occur late after initiation of the angiostatic treatment and
are therefore a poor readout of early drug efﬁcacy. The
effects of the new drug on the tumor vasculature can be
assessed by ex vivo analysis of the tumor microvessel
density (MVD). Several angiogenesis inhibitors, including
endostatin and anginex (Anx), have shown to decrease the
tumor MVD, which is therefore considered a parameter
that may be used to predict therapeutic effect [5, 9]. A
major drawback of the MVD readout is that—as with all
histological analyses—it can only be determined with
invasive and laborious procedures following staining of ex
vivo tumor tissue sections, making it difﬁcult to assess
tumor vessel density heterogeneity and precluding longi-
tudinal assessment during the course of treatment. There-
fore, noninvasive imaging methods that report on tumor
angiogenesis are highly desired, since methods to visualize
and quantify angiogenic activity in vivo would allow lon-
gitudinal monitoring and thus facilitate the early evaluation
of a given angiostatic therapy. For this purpose, magnetic
resonance imaging (MRI) is a prime candidate.
MRI is a powerful noninvasive imaging modality
capable of generating high-resolution images with superb
soft tissue contrast. Already, MRI offers a broad spectrum
of techniques to localize, visualize and characterize tumors.
For example, anatomical T2-weighted images help to
deﬁne anatomical borders of solid tumors with outstanding
resolution and contrast, and aid in distinguishing and
classifying healthy from diseased tissue [10]. Also MR
spectroscopy can be used to assess tumor pH and metabolic
activity [11]. MR image contrast reﬂecting endogenous
cellular protein and peptide content in the tumor can be
produced by selective radiofrequency labeling of the pro-
tein and peptide amide protons and exploiting the magne-
tization transfer to water via hydrogen exchange [12].
Recent advances in whole-body diffusion-weighted imag-
ing show promise for diagnosing lesions throughout the
entire human body as well as for assessing lymph node
metastases, with superior spatial resolution, and sensitivity
and speciﬁcity that rival FDG-PET imaging [13]. In addi-
tion, hemodynamic parameters such as the fractional blood
volume, vascular permeability, tumor blood perfusion, and
lymphatic drainage can be assessed using contrast-
enhanced MRI [14–16].
Recent advances in molecular imaging—the ﬁeld that
aims to noninvasively visualize processes at the molecular
and cellular level—have broadened the use of MRI in
oncology [16–18]. Sophisticated contrast agents have been
developed, equipped with targeting ligands directed toward
angiogenesis-speciﬁc markers, which allow for noninva-
sive in vivo visualization of the angiogenic activity in the
tumor. A variety of targeted Gd-, ironoxide-, and ﬂuorine-
based MRI contrast agents have been developed for this
purpose, ranging from low molecular weight agents to
nanoparticulate agents of different size and composition
[19–30].
In this paper, we review our recent work on the use of
multimodal liposomes for target-speciﬁc preclinical imag-
ing of tumor angiogenesis and therapy. Over the last dec-
ades, liposomes were extensively studied as drug carriers
for cancer therapy [31]. Encapsulation of the drug in a
liposome improves the pharmacokinetic proﬁle, thereby
increasing the amount of drug effectively delivered to the
tumor, while preventing rapid clearance, drug degradation,
and inactivation. When equipped with a high payload of
contrast generating material and conjugated with one or
more types of targeting ligands, liposomes turn into a
potent contrast agent for tumor angiogenesis imaging.
Often, the liposomes are endowed with a contrast agent for
a complementary imaging modality, e.g., ﬂuorescence
imaging, for validation purposes and to investigate binding
and accumulation at the cellular level. Combined with
angiostatic drugs, these multimodal liposomes allow for
image-supervised drug delivery and monitoring of angio-
static therapy.
Multimodal liposomes for visualization of tumor
angiogenesis
A liposome is a spherical vesicle composed of a bilayer of
naturally occurring phospholipids or closely related syn-
thetic amphiphiles enclosing an aqueous interior [32, 33].
For in vivo application purposes, the liposome should be
biocompatible, stable, and possess favorable pharmacoki-
netic properties. Therefore, liposomes are usually com-
prised of components that energetically favor a bilayer
organization, such as phospholipids comprising a polar
head group and two fatty acyl chains [33]. For additional
stabilization, cholesterol is commonly included [33]. To
reduce interactions with blood circulating proteins and
162 Angiogenesis (2010) 13:161–173
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incorporated, which increases the liposome blood circula-
tion half-life and ensures optimal pharmacokinetics
[34, 35].
Liposomes are commonly prepared by a lipid ﬁlm
hydration technique. The preparation involves several
steps. First, the appropriate amounts of lipids are dissolved
and mixed in an organic solvent, e.g., chloroform or
chloroform/methanol. The organic solvent is then removed
by rotary evaporation yielding a thin lipid ﬁlm on the sides
of a round bottom ﬂask. Next, the lipid ﬁlm is hydrated by
addition of an aqueous medium at a temperature above the
lipid gel-liquid crystal transition temperature, resulting in a
solution of multilamellar lipid vesicles. Finally, the mul-
tilamellar vesicles are downsized by extrusion of the lipid
suspension through a polycarbonate ﬁlter of well-deﬁned
pore size at elevated temperature or by sonication to yield a
suspension of liposomes with a narrow and well-deﬁned
size distribution.
Initially, MRI contrast properties were introduced in
liposomes by enclosing low molecular weight Gd- and Mn-
based contrast agent in the aqueous interior [36–44]. The
applicability of these liposomal MRI contrast agents was,
however, limited because entrapment of the Gd and Mn
effectively leads to very low relaxivity—the parameter that
deﬁnes the potency of the agent to introduce contrast in the
MR images—due to limited water exchange across the
liposomal bilayer. Moreover, the entrapped contrast agent
may leak out. An alternative approach is therefore to
include Gd entities in the liposomal bilayer. A number of
Gd-containing amphiphiles have been developed for this
purpose [45–49]. We introduced a paramagnetic liposome
of which the schematic design is shown in Fig. 1 [50]. The
liposomal bilayer consisted of DSPC, PEG2000-DSPE,
maleimide-PEG2000-DSPE, cholesterol, and 25 mol% Gd-
DTPA-di(stearylamide). The presence of this high payload
of Gd-containing lipids ensures a high particulate relaxiv-
ity. Half of the Gd-DTPA-di(stearylamide) is contained in
the outer bilayer with free access to solute water and
therefore the relaxivity is much less exchange limited.
Fluorescent properties were introduced by addition of
0.1 mol% rhodamine PE. The size of these liposomes was
120 nm. In a follow-up study, these liposomes were further
characterized concerning morphology and relaxivity [51].
Hak et al. [52] have recently designed a liposome con-
taining Gd-DOTA-DSPE which, in contrast to Gd-DTPA-
di(stearylamide), exhibited no detectable transmetallation
upon exposure to Zn ions in the presence of phosphate ions.
This is an important improvement to the safety of the
agent, as transmetallation in the presence of phosphate
anions has been proposed as a likely mechanism underly-
ing nephrogenic systemic ﬁbrosis (NSF), a severe disorder
associated with the use of Gd-based contrast agents in
patients with end-stage renal disease [53]. Additionally,
liposomes with Gd-DOTA-DSPE displayed a considerable
higher relaxivity [52].
Speciﬁcity for tumor angiogenesis can be introduced by
decorating the exterior of the liposomes with suitable tar-
geting ligands, e.g., antibodies or peptides, as schemati-
cally illustrated in Fig. 1. Covalent binding of the targeting
ligands to the liposome is achieved by coupling to lipids
with a functional reactive group, such as maleimide, thiol,
amine, or carboxylic acid. Targeted liposomal MRI con-
trast agent can be used to follow the effects of therapeutic
interventions, as will be discussed in detail further on.
Imaging and therapy may be combined by inclusion of
drugs in the liposomal formulation. Water-soluble drug can
be enclosed in the liposomal interior. Drugs may also be
enclosed in the liposomal bilayer or attached to the distal
end of the PEG chains (Fig. 1).
Multimodal imaging of tumor angiogenesis
and angiostatic therapy
Many studies, which aimed at in vivo visualization of the
molecular hallmarks of tumor angiogenesis, have focused
on the avb3 integrin [19, 20, 29, 30, 54–63]. The avb3
integrin is strongly expressed on the activated endothelium
of angiogenic blood vessels and is involved in many tumor
related processes. Importantly, the integrin is only weakly
expressed on resting endothelial cells in nondiseased tissue,
making it an attractive speciﬁc target for tumor angio-
genesis imaging [64]. MR imaging of tumor angiogenesis
using a targeted paramagnetic vesicles was pioneered by
Sipkins et al. [19]. They demonstrated enhanced and
detailed imaging of the avb3 expressing angiogenic vas-
culature in rabbit carcinomas after intravenous adminis-
tration of the aforementioned agent, providing a
noninvasive means to assess the growth and malignant
phenotype of tumors. The avb3 integrin binds to a wide
variety of extracellular matrix proteins, which expose the
tripeptide sequence Arg-Gly-Asp (RGD) as a common
receptor recognition signal [65]. This peptide is used as a
targeting moiety for angiogenesis targeting and several
isoforms that include the tripeptide sequence have been
developed. A cyclic conformation (cyclic RGD) has
favorable binding properties when compared to a linear
peptide and multimers of the RGD peptide have been
shown to increase the afﬁnity and speciﬁcity [56, 57, 66].
A bimodal, MRI and ﬂuorescence, approach to tumor
angiogenesis imaging was applied by Mulder et al. [22]. As
a bimodal contrast agent, the above-described liposomes
were used, which have a high payload of Gd-containing
lipid for MRI purposes and rhodamine ﬂuorescent lipids for
optical imaging. The 150-nm-diameter liposomes were
Angiogenesis (2010) 13:161–173 163
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per particle to introduce speciﬁcity for the avb3 integrin.
The high number of RGD moieties attached to the lipo-
somes ensures a high afﬁnity for the target on the basis of
multivalency.
The targeting and multimodal-imaging concept was ﬁrst
tested in vitro using human endothelial cells (human
umbilical vein endothelial cells). Cells incubated with
speciﬁc RGD-conjugated liposomes displayed bright rho-
damine ﬂuorescence, which was lacking in case of control
incubations with nonspeciﬁc RAD-conjugated liposomes.
Detailed analysis showed that the RGD-conjugated lipo-
somes were internalized in the perinuclear region of the
cells. MR imaging of cell pellets revealed a large contrast
between speciﬁc and control incubations. Application of
RGD-conjugated liposomes resulted in a substantial T1-
relaxation time shortening of the cell pellets. These results
proved speciﬁcity and high afﬁnity for endothelial cells.
The mechanism of RGD-conjugated liposome uptake and
the effect of internalization on the relaxation properties
were further investigated in two recent studies [67, 68]. A
dramatic lowering of the longitudinal relaxation rate r1
(relaxivity quenching) for cell-internalized targeted lipo-
somes was observed that warrants caution in the quantita-
tive interpretation of the observed MRI signal.
In vivo angiogenesis imaging was performed on sub-
cutaneous xenograft human LS174T colon carcinoma
tumors in athymic mice (Fig. 2). After initial localization
of the tumor on the right ﬂank of the mouse using a T2-
weighted scan, repeated high-resolution T1-weighted ima-
ges were recorded pre- and post-intravenous injection of
RGD-conjugated liposomes (Fig. 2a). A pixel-by-pixel
comparison of pre- and post-injection images, revealed
those pixels that were signiﬁcantly enhanced by the para-
magnetic liposomes. After injection of RGD-conjugated
liposomes, the pixels that showed enhancement were
mainly located in the rim of the tumor (Fig. 2a), whereas
for injections with nonspeciﬁc RAD-conjugated liposome
enhancement was more evenly distributed through the
tumor volume (Fig. 2b). Injection of RGD-conjugated
liposomes did not lead to a signiﬁcant amount of enhanced
pixels when the mice were pretreated with MRI-invisible
nonparamagnetic RGD-conjugated liposomes to block the
avb3 binding of paramagnetic RGD-conjugated liposomes
(Fig. 2c).
The in vivo MRI ﬁndings as shown in Fig. 2 strongly
suggested that RGD-conjugated liposomes predominantly
accumulated in the tumor through a speciﬁc interaction.
Proof for exclusive association with the angiogenic endo-
thelium of the tumor blood vessels, however, was not
provided by the in vivo experiments. Here, the true power
of a multimodal contrast agent comes into play, in this case
combining the in vivo MRI ﬁndings with ex vivo ﬂuores-
cence microscopy. Fluorescence microscopy revealed dis-
tinct differences in the localization of the liposomes in the
tumors of mice injected with RGD- or RAD-conjugated
liposomes. RGD-conjugated liposomes were found exclu-
sively associated with tumor blood vessels (Fig. 3a, b),
suggesting speciﬁc association with avb3 integrin expres-
sed on the endothelial cells. In the center of the tumor
(Fig. 3c) almost no liposomal ﬂuorescence was observed,
in agreement with the in vivo MRI ﬁndings. Fluorescence
from the RAD-conjugated liposomes was observed more
diffusely spread beyond the vasculature of the tumor
(Fig. 3d), indicative for nonspeciﬁc extravasation. Extrav-
asation of RAD-conjugated liposomes was further facili-
tated by a longer circulation time when compared to RGD-
conjugated liposomes [69].
In a follow-up study, the above avb3 integrin speciﬁc
RGD-conjugated liposomes were used for noninvasive
evaluation of the efﬁcacy of angiogenesis inhibitors during
the course of therapy [24]. Again, in vivo MRI and ex vivo
Fig. 1 Schematic representation of a target-speciﬁc multimodal
liposome for combined angiogenesis imaging and therapy. Generally,
the liposome contains a high payload of Gd containing lipids and
ﬂuorescent lipids for MRI and ﬂuorescence microscopy, respectively.
The liposome can be equipped with single or multiple populations of
antibodies or peptides to introduce target speciﬁcity, biotin for an
avidin-induced clearance strategy, as well as with drugs in the lumen,
in the bilayer or by covalent binding to the distal ends of the PEG
chains
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liposomes were fully exploited to image ongoing angio-
genesis during the treatment. B16F10 mouse melanoma
tumors were grown on the ﬂank of C57BL/6 mice. An-
giostatic therapy consisted of treatment for 3 or 14 days
with either endostatin or anginex (Anx). The percentage of
enhanced pixels in the tumor after injection with para-
magnetic and ﬂuorescent RGD-conjugated liposomes
served as a noninvasive in vivo readout of angiogenic
activity (Fig. 4b). Ex vivo ﬂuorescence microscopy proved
speciﬁc association with the tumor blood vessels. As a gold
standard for assessing the angiogenic activity, the micro-
vessel density (MVD) was determined by ex vivo staining
tumor blood vessels with CD31 antibody and counting their
density (Fig. 4a). MVD revealed a signiﬁcant treatment
effect for anginex (3 and 14 days treatment) and endostatin
(3 days treatment). Importantly, the in vivo MRI readout of
angiogenic activity closely reﬂected the treatment effects
as deduced from the ex vivo analyses, proving that the
multimodal liposomes can be used to noninvasively mon-
itor efﬁcacy of angiostatic therapy.
Improving target speciﬁcity by avidin-induced
clearance of circulating liposomes
The RGD-conjugated liposomes for imaging angiogenesis,
as described in the previous section, were designed to
exhibit a long blood circulation half-life, which was
achieved by including PEG-lipids in the liposomal bilayer.
Fig. 2 In vivo visualization of tumor angiogenesis by application of
avb3 integrin-targeted paramagnetic and ﬂuorescent liposomes. a MR
images of three slices through a mouse with a xenograft human
LS174T colon carcinoma in a subcutaneous location on the right
ﬂank. The images were taken 35 min after injection of RGD-
conjugated liposomes, which target the avb3 integrins expressed on
the angiogenic tumor endothelium. Pixels in the tumor that were
signiﬁcantly enhanced by the presence of the paramagnetic liposomes
were highlighted and color coded according to the scale on the right.
Enhancement was mainly found at the rim of the tumor in
correspondence with the spatial distribution of angiogenic blood
vessels. The percentage of enhanced pixels serves as a noninvasive
readout of angiogenic activity. b MR images of a mouse 35 min after
injection with nonspeciﬁc RAD-conjugated liposomes. Nonspeciﬁc
liposomes distributed more evenly throughout the whole tumor. c MR
images of a mouse 35 min after pretreatment with nonparamagnetic
RGD-conjugated liposomes to block the avb3 integrin followed by
injection with paramagnetic RGD-conjugated liposomes. Only a
small number of pixels showed signal enhancement proving speci-
ﬁcity of the avb3 targeting concept. Adapted from Ref. [22] with
permission
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microscopy of dissected tumors
of mice, which were injected
with paramagnetic, ﬂuorescent,
RGD- or RAD-conjugated
liposomes. a, b In the rim of the
tumors, the red rhodamine
ﬂuorescence originating from
the RGD-conjugated liposomes
revealed circular and
longitudinal distribution
patterns associated with blood
vessels. Cell nuclei were stained
with DAPI (blue ﬂuorescence).
c A slice through the middle of
the tumor revealed no
ﬂuorescence from RGD-
conjugated liposomes, in
agreement with a lack of
angiogenic blood vessels in this
location. d A diffuse pattern of
ﬂuorescence was observed in
tumors of mice injected with
nonspeciﬁc RAD-conjugated
liposomes, indicative for
nonspeciﬁc distribution beyond
the blood vessels throughout the
whole tumor. Adapted from
Ref. [22] with permission
Fig. 4 In vivo assessment of angiostatic therapy efﬁcacy by targeted
multimodal liposomes. Mice with a B16F10 melanoma tumor in a
subcutaneous position on the right ﬂank were treated for 3 or 14 days
with either anginex or endostatin, which both are angiostatic
compounds. a Microvessel density (MVD, mean number of vessels
per 0.25 mm
2) was determined by ex vivo staining of tumor blood
vessels with CD31 antibody and counting their density. (b) The
percentage of enhanced pixels in the tumor on T1-weighted MRI after
injection with paramagnetic RGD-conjugated liposomes served as a
noninvasive in vivo readout of angiogenic activity (see also Fig. 2).
MVD revealed a signiﬁcant treatment effect for anginex (3 and
14 days treatment) and endostatin (3 days treatment). Importantly, the
in vivo MRI readout of angiogenic activity closely reﬂected the
treatment effects as deduced from the ex vivo analyses, proving that
the multimodal liposomes can be used to noninvasively monitor
angiostatic therapy. Adapted from Ref. [24] with permission
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advantageous for molecular imaging as it may increase the
amount of contrast agent that accumulates at the angio-
genic site enabled by prolonged time for interaction with
the targets. This is particularly necessary for MRI, since
this is a relatively insensitive technique for the detection of
low concentrations of contrast agent. On the other hand, the
MR images will suffer from undesired background signal
because of circulating liposomes, resulting in a suboptimal
target-to-background ratio. The use of ﬂow suppression
techniques potentially can solve this problem. However,
low ﬂow velocity, reduction of the blood T1-relaxation
time by the liposomes, and the complex and unstructured
vasculature of the tumor blood vessels makes ﬂow-sup-
pression unreliable in tumors. Additionally, control lipo-
somes generally display different blood-clearance rates,
complicating a straightforward comparison between tar-
geted and control particles. Ideally, the nonbound fraction
should be cleared from the blood stream as soon as sufﬁ-
cient liposomes have associated with the target site. This
would signiﬁcantly enhance the speciﬁcity of the targeted
liposomes for molecular imaging of angiogenesis. Fur-
thermore, this approach would enable investigations into
the accumulation kinetics of targeted liposomes and the
optimization of MR imaging protocols for their detection.
A strategy to achieve rapid clearance of nonbound lip-
osomes from the vasculature was developed by van Tilborg
et al. [70, 71]. The technology is based on a so-called
avidin chase experiment. Avidin is a 66-kDa glycoprotein,
which can bind four biotin molecules with high afﬁnity
(Kd\10
-15 M) [72]. Avidin alone displays a very short
intrinsic blood-circulation half-life, accumulates in the
liver, spleen and kidneys, and is subsequently cleared from
all organs within a couple of days [72, 73]. The basic idea
is to equip the liposomal contrast agent with a targeting
ligand, as well as with biotin. After initial intravenous
injection of the agent, the liposomes are allowed to spe-
ciﬁcally bind and accumulate at the desired target site. In a
second step, avidin is injected which then binds with high
afﬁnity to the biotin on the liposomes. As a consequence,
the avidin triggers fast clearance of the circulating, non-
target-associated liposomes from the blood. This clearance
strategy has been previously successfully applied to radi-
olabeled antibodies [74, 75] and liposomes [76] for nuclear
imaging, as well as to dendrimer-based [77] and albumin-
based [14] agents for MR imaging.
The avidin-chase technology was shown to improve the
speciﬁcityofinvivomolecularmagneticresonanceimaging
ofangiogenesisusingtargeted multimodalRGD-conjugated
liposomes [71]. For this purpose, the RGD-conjugated lip-
osomes were additionally equipped with biotin-PEG2000-
DSPE (RGD-biotin-liposomes). In Fig. 5, the experiments
are summarized. Tumor-bearing mice were intravenously
injected with either RGD-biotin-liposomes or biotin-lipo-
somes. After 100 min of circulation time, the mice received
an intravenous infusion of avidin over a period of approxi-
mately 15 min to induce rapid blood clearance of the lipo-
somes. Mice not infused with avidin served as controls. The
RGD-biotin-liposome injection resulted in contrast
enhancement mainly in the rim of the tumor, in agreement
with the expected distribution of angiogenic blood vessels
(Fig. 5a). The enhancement pattern changed only slightly
between the 90- and 150-min time points after injection of
the liposomes. In contrast, when avidin was infused at
100 minafterinjection,thepercentageofenhancedpixelsin
the tumor decreased and enhanced pixels became more
localized in the rim of the tumor (Fig. 5b), which suggests
that part of the enhancement observed at the 90-min time
point was caused by circulating liposomes. In Fig. 5c and d,
the time lines of enhancement are summarized for the dif-
ferent experimental groups. Without application of the avi-
din chase (Fig. 5c), enhancement after injection of RGD-
biotin-liposomes as well as biotin-liposomes decreases only
slightly over the 150-min experimental time. After appli-
cation of the avidin chase (Fig. 5d), the enhancement
induced by the nonspeciﬁc biotin-liposomes was reduced to
almost base levels, while the enhancement by RGD-biotin-
liposomeswasstillsigniﬁcant, withamuchhighertarget-to-
backgroundratio. Themultimodalliposomeswere equipped
with a ﬂuorescent lipid as well and subsequent ex vivo
ﬂuorescence microscopy conﬁrmed above interpretations.
This clearance strategy can be used to study relative
contributions of target-associated, extravasated, as well as
circulating nonbound liposomes to the MRI contrast
enhancement in the tumor tissue. The avidin-chase tech-
nology can be applied to remove the blood pool component
in the contrast-enhanced MRI experiment where ﬂow
suppression is not sufﬁcient, which opens exciting possi-
bilities for studying detection limits and angiogenesis tar-
geting kinetics of the liposomal contrast agents.
Synergistic targeting for combined imaging and
treatment
Despite the major advances with the introduction of mul-
timodal targeted liposomes, the modest amounts of target-
associated contrast material still remains an obstacle for
widespread application of molecular imaging of tumor
angiogenesis. Recently, Kluza et al. [78] introduced a novel
concept which may, at least partly, help to alleviate the
sensitivity and speciﬁcity problems. The idea was to
involve several different molecular markers speciﬁc for
angiogenesis in the targeting process. The activated endo-
thelium of angiogenic blood vessels seems to be an
excellent candidate for this synergistic targeting concept as
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geting of multiple receptors is relatively new in the ﬁeld of
molecular imaging and has been investigated before in a
few studies only concerning drug delivery to cells [81, 82],
for MR imaging of atherosclerosis [83], and for ultrasound
imaging of tumor angiogenesis [84].
Moreover, for the ﬁrst time Kluza et al. [78] showed that
synergistic targeting with liposomes could be used to
combine imaging and treatment of angiogenesis. This was
achieved by using a unique combination of two targeting
ligands, RGD and anginex (Anx), which bind speciﬁcally
to two important angiogenic markers, avb3 and galectin-1,
respectively, and exert angiostatic activity as well [7, 85].
Similar to aforementioned studies, the liposomes were of a
bimodal nature containing a high payload of Gd-containing
lipid for MR imaging and ﬂuorescent lipids for ﬂuorescent
imaging, which enabled extensive evaluation and valida-
tion of the applied strategy.
The effects of simultaneous targeting of avb3 and
galectin-1 on the cellular uptake of the bimodal liposomes
were investigated in vitro using human endothelial cells
and the main results are summarized in Fig. 6. In the
experiment, the targeting efﬁcacy of the dual-targeted lip-
osomes was compared to single-targeted liposomes to
demonstrate the synergistic effect. Additionally, the dif-
ference between two dual-targeting strategies was studied.
In the ﬁrst approach, both RGD and Anx were conjugated
to the same liposomes, whereas in the second, a mixture of
single-conjugated RGD- and Anx-liposomes was used for
targeting. Figure 6a schematically depicts the different
experimental groups, which also included high and low
concentrations of targeting peptides. Figure 6b shows a
Fig. 5 Improved MR imaging of tumor angiogenesis by avidin-
induced clearance of nonbound liposomes. a, b T2-weighted (T2-w,
left) and T1-weighted MR images (right) of a mouse with a B16F10
melanoma tumor in a subcutaneous position on the right ﬂank
(arrow). a Images of a mouse 90 and 150 min after intravenous
injection of liposomes conjugated with both RGD peptide as well as
biotin (RGD-biotin-liposomes). The signiﬁcantly enhanced pixels are
color coded according to the scale on the right. b Images of a mouse
after intravenous injection of RGD-biotin-liposomes. Between the 90-
and 150-min time points, nonbound liposomes were removed by an
intravenous infusion of avidin, which binds with high afﬁnity to the
biotin on the liposomes and induces rapid blood clearance. c Time
dependence of the percentage of enhanced pixels after injection with
RGD-biotin-liposomes or liposomes with biotin only (biotin-lipo-
somes). d Time dependence of the percentage of enhanced pixels
after injection with RGD-biotin-liposomes and biotin-liposomes.
After 100 min of circulation, the mice received and intravenous
infusion of avidin over a period of approximately 15 min (gray bar)
to induce clearance of nonbound liposomes. Figure adapted from Ref.
[71] with permission
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after 3 h incubation at 37C. The quantitative concentra-
tion of Gd taken up by the cells provided an MRI-relevant
indicator for the uptake of the paramagnetic liposomes.
The highest uptake of Gd was observed for the Anx and
RGD dual-conjugated liposomes with high peptide con-
centration (condition 5). The synergistic effect is clearly
visible by comparing condition 5 with 7. Incubations with
a mixture of single-targeted RGD- and Anx-liposomes led
to additive increase in Gd concentration when compared to
the individual incubations (conditions 3 and 4). The dual-
targeted liposomes (condition 5), however, resulted in
approximately two-fold higher Gd uptake. Fluorescence
microscopy provided additional evidence for the
synergistic effect as shown in Fig. 6c. Highest levels of
liposomal rhodamine ﬂuorescence were observed in cells
incubated with the dual-targeted liposomes (conditions 5
and 6) in agreement with the quantitative analyses.
Angiostatic potential of the RGD and Anx dual-con-
jugated liposomes was assessed by performing cell cycle
analyses to investigate the antiproliferative effects
induced by the synergistic effects of RGD and Anx. As
readout to assess the therapeutic outcome, the percentages
of cells in the S (DNA replication phase) and the G2/M
(interphase/mitosis) phases were used. A decrease in S
and G2/M phase is generally considered a hallmark of
impaired proliferation. A considerable reduction was
found for treatments with the dual-targeted liposomes,
Fig. 6 Synergistic targeting of avb3 integrin and galectin-1 with
heteromultivalent paramagnetic liposomes for combined imaging and
treatment of angiogenesis. a Schematic representation of the incuba-
tion schemes of in vitro human endothelial cells, for the following
conditions: 1. Culture medium [Control]; 2. Nontargeted liposomes
[Bare-L]; 3. Anx-conjugated liposomes [Anx-L]; 4. RGD-conjugated
liposomes [RGD-L]; 5. Anx and RGD dual-conjugated liposomes
containing high concentration of peptides [Anx/RGD L (H)]; 6. Anx
and RGD dual-conjugated liposomes containing low concentration of
peptides [Anx/RGD-L (L)]; 7. Mixture of Anx-L and RGD-L
containing high concentration of peptides [mixed Anx-L ? RGD-L
(H)]; 8. Mixture of Anx-L and RGD-L containing low concentration
of peptides [mixed Anx-L ? RGD-L (L)]. High concentration of
peptides (H) were 10 lg/lmol lipid of Anx and 3 lg/lmol lipid of
RGD, while low concentration (L) corresponded to 5 lg/lmol lipid of
Anx and 1.5 lg/lmol lipid of RGD. b Gd uptake levels achieved with
the different targeting strategies. Highest uptake of liposomal Gd was
achieved for condition 5, demonstrating the synergistic effect of the
two targeting ligands. c Fluorescence microscopy images of human
endothelial cells incubated under the different conditions. Cell nuclei
were stained with DAPI (blue ﬂuorescence) and red ﬂuorescence
originated from the rhodamine-labeled liposomes. Highest cell
associated red ﬂuorescence was again observed for Anx and RGD
dual-conjugated liposomes containing high concentration of peptides
(condition 5). Adapted from Ref. [78] with permission
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123which was stronger, however, not signiﬁcantly, when
compared to the single-conjugated liposomes. The syn-
ergistic effects of these dual-targeted liposomes create a
great opportunity for their use in combined imaging and
therapy of angiogenesis.
Summary and perspective
This paper reviewed our recent strategies on the design and
application of multimodal targeted-liposomes for in vivo
visualization, quantiﬁcation, and treatment of tumor angio-
genesis. As an angiogenesis-speciﬁc targeting ligand, we
mainly used the cyclic RGD peptide, which binds with high
speciﬁcity to the avb3 integrins expressed on angiogenic
endothelium. Liposomes conjugated with a few hundred of
these RGD peptides were shown to bind with great speci-
ﬁcity to mouse tumor vascular endothelium. This enabled
speciﬁc in vivo MRI visualization of angiogenic activity in
tumors. Multimodality imaging properties were introduced
by addition of ﬂuorescent labels in the liposomes. This
proved an essential tool for validation purposes, as it com-
binedthebestofbothworlds—invivoMRimagingoftumor
angiogenesis with ex vivo ﬂuorescence imaging of the
liposomal accumulation and fate at the cellular level. Fur-
thermore, the RGD-conjugated liposomes were applied for
invivovisualizationofchangesintumorangiogenicactivity
after treatment with several angiostatic compounds.
The PEG-coated liposomes exhibit long in vivo blood
circulation times. This can be exploited to increase the
amount of contrast agent that accumulates at the angiogenic
site. However, background MR signal from circulating lip-
osomes in the blood pool reduces the target-to-background
ratio. Incorporation of biotin-PEG-lipids in the bilayer was
used for fast clearance of the liposomes from the blood pool
using an avidin chase. This strategy improved the speciﬁcity
of the MR readout and increased the target-to-background
ratio dramatically. Finally, liposomes were equipped with
two types of angiogenesis-speciﬁc ligands, i.e., RGD and
anginex. First of all, this improved targeting efﬁcacy by
synergistic effects of the two targeting ligands. Second, the
dual-targeted liposomes exhibited considerable angiostatic
effects and therefore can be used for combined tumor
angiogenesis imaging and therapy.
The reviewed work convincingly demonstrated that
molecular MRI of angiogenesis and therapy monitoring in
mouse models of cancer are feasible using the multimodal
targeted liposomes. In recent years, several competitive
platforms have been introduced in the ﬁeld of nanoparticle-
based molecular imaging. Some examples are iron-oxides
[86], perﬂuorocarbon nanoparticles [63], polymeric nano-
carriers [87], viruses [88], and high-density lipoprotein-
based nanoparticles [89, 90]. In our work, we have mainly
focused on small peptides as targeting ligand for angio-
genesis.Alternative ligands include antibodies and antibody
fragments[91],smallmolecules[92],peptidomimetics [93],
aptamers [94], and nanobodies [95]. This multi-disciplinary
ﬁeld of molecular imaging is evolving very fast and whether
a given nanoparticle-ligand combination will be successful
eventually remains to be evaluated for each particle
separately.
Therefore, there is still a long way to go before this
technology can be translated to human cancer. In particu-
lar, more knowledge is needed on the long-term fate of the
bound and cell-internalized nanoparticles and on the organ-
clearance kinetics and pathways in view of possible tox-
icity issues. Nevertheless, a lot of knowledge can be gained
from preclinical studies in mouse models of cancer and for
this the in vivo angiogenesis imaging technology proves a
valuable tool already.
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